CN110859912A - 一种用于***炎的中药组合物及其制备方法和应用 - Google Patents
一种用于***炎的中药组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN110859912A CN110859912A CN201911358094.9A CN201911358094A CN110859912A CN 110859912 A CN110859912 A CN 110859912A CN 201911358094 A CN201911358094 A CN 201911358094A CN 110859912 A CN110859912 A CN 110859912A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- medicine composition
- parts
- prostatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 85
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000000126 substance Substances 0.000 claims abstract description 10
- 210000002307 prostate Anatomy 0.000 claims description 30
- 239000000843 powder Substances 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 16
- 238000010298 pulverizing process Methods 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 12
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 12
- 241000196324 Embryophyta Species 0.000 claims description 11
- 238000002791 soaking Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 241000241413 Propolis Species 0.000 claims description 9
- 229940069949 propolis Drugs 0.000 claims description 9
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 8
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 244000144927 Aloe barbadensis Species 0.000 claims description 7
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 7
- 229920001661 Chitosan Polymers 0.000 claims description 7
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 7
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 7
- 235000011399 aloe vera Nutrition 0.000 claims description 7
- 229960004999 lycopene Drugs 0.000 claims description 7
- 235000012661 lycopene Nutrition 0.000 claims description 7
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 7
- 239000001751 lycopene Substances 0.000 claims description 7
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 7
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 6
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 6
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 244000144730 Amygdalus persica Species 0.000 claims description 5
- 229920000157 polyfructose Polymers 0.000 claims description 5
- 244000269722 Thea sinensis Species 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 238000002390 rotary evaporation Methods 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 241000255789 Bombyx mori Species 0.000 abstract description 19
- 235000004298 Tamarindus indica Nutrition 0.000 abstract description 18
- 240000004528 Catalpa ovata Species 0.000 abstract description 17
- 235000010005 Catalpa ovata Nutrition 0.000 abstract description 17
- 241001013934 Erigeron breviscapus Species 0.000 abstract description 10
- 235000013399 edible fruits Nutrition 0.000 abstract description 7
- 208000017497 prostate disease Diseases 0.000 abstract description 4
- 230000003750 conditioning effect Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 240000004584 Tamarindus indica Species 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 38
- 238000011282 treatment Methods 0.000 description 27
- 230000000694 effects Effects 0.000 description 25
- 230000027939 micturition Effects 0.000 description 19
- 241000596504 Tamarindus Species 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 230000036039 immunity Effects 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 230000036541 health Effects 0.000 description 9
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 208000013507 chronic prostatitis Diseases 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 241000382353 Pupa Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 7
- 229940067606 lecithin Drugs 0.000 description 7
- 239000000787 lecithin Substances 0.000 description 7
- 235000010445 lecithin Nutrition 0.000 description 7
- 206010063057 Cystitis noninfective Diseases 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 241000132521 Erigeron Species 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010025 steaming Methods 0.000 description 5
- 239000011573 trace mineral Substances 0.000 description 5
- 235000013619 trace mineral Nutrition 0.000 description 5
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 4
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 4
- 206010018691 Granuloma Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010062225 Urinary tract pain Diseases 0.000 description 3
- 238000001467 acupuncture Methods 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 210000003815 abdominal wall Anatomy 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 239000006014 omega-3 oil Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 206010069918 Bacterial prostatitis Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000723422 Catalpa Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000723377 Coffea Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010057672 Male sexual dysfunction Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 210000004908 prostatic fluid Anatomy 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000008554 xiao zhi ling Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Insects & Arthropods (AREA)
- Molecular Biology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于中药技术领域,涉及一种用于***炎的中药组合物及其制备方法和应用,组合物包括如下重量份的各物质:蚕蛹20‑50份、酸角10‑50份、梓实20‑60份、铁灯盏10‑50份。本申请的组合物利用了每一组方药物的特性,并通过整体调理体质,达到缓解、治愈***疾病的目的。
Description
技术领域
本发明属于中药技术领域,特别是涉及一种用于***炎的中药组合物及其制备方法和应用。
背景技术
***炎是男性成年人的多发病,也是泌尿外科的常见病,治疗效果差。从临床发病率来看,甚至大部分老年性***良性增生患者也伴有***炎。本病与男性性功能障碍(***减退,早泄,***疼痛,遗精)的发生有密切关系。1995年美国国立卫生研究院(NIH)制定了一种新的***炎分类方法,I型:急性细菌性***炎,Ⅱ型:慢性细菌性***炎,Ⅲ型:慢性非细菌性***炎,Ⅳ型:无症状性***炎。其中慢性非细菌性***炎是***炎中最常见的类型,约占慢性***炎的90%以上。该病的临床表现主要为尿频、尿急、尿痛、排尿无力、尿线细、淋漓不尽等。虽然它不是一种直接威胁生命的疾病,但是对患者的身心健康影响很大,常伴有神经和精神症状。美国国立卫生研究院(Nationalinstitute of health,NIH)目前已将慢性***炎和心肌梗死、不稳定性心绞痛、活动性Crohn病等一起列为影响居民生活质量最为严重的慢性疾病。随着生活水平的提高,饮食结构的改变,***疾病发病率有日益增高的趋势,做好防治工作,降低***疾病发病率,对提高生活质量是非常重要的。
目前,治疗***炎的方法有口服药物、抗生素治疗、针灸治疗、物理治疗、注射治疗等,由于***脂膜的屏障作用,大多数抗菌药物难以进入***内达到有效的抑菌浓度,只有脂溶性高的碱性药物,与血浆蛋白结合少,离解度高的药物,对***脂膜弥散性好的药物才有可能发挥较好的疗效。由于许多抗生素难以透过***的脂质包膜,因此,有的医生采取直接把抗菌药注入***内以治疗***炎,取得一定的疗效,但注射治疗必须由泌尿外科医生进行操作,技术要求比较高,患者痛苦大。针灸治疗需专门的针灸医师方可实施,这对皮肤敏感者容易产生刺激,物理治疗有利于炎症的消散,但无法达到治愈不复发的效果,
发明内容
本申请提供一种用于***炎的中药组合物及其制备方法和应用,其是针对慢性***炎患者存在的尿急、尿频、尿痛、膀胱发炎、下腹部胀痛等症状的改善,从而提高患者的生活质量。
为实现上述技术目的,本申请采取的技术方案为:一种用于***炎的中药组合物,包括如下重量份的各物质:
蚕蛹 20-50份
酸角 10-50份
梓实 20-60份
铁灯盏 10-50份。
作为本申请改进的技术方案,还包括辅料,辅料包括植物甾醇、γ-氨基丁酸、番茄红素、多聚果糖、低聚半乳糖、蜂胶、壳聚糖、桃胶或库拉索芦荟凝胶中的一种或多种。
作为本申请改进的技术方案,所述辅料的总重量份为0.9-5.6份。
作为本申请改进的技术方案,所述中药组合物采用代用茶、颗粒剂、胶囊剂、片剂或散剂形式呈现。
本申请的另一目的在于提供一种用于***炎的中药组合物的制备方法,所述中药组合物采用各成分的活性物质提取物制备而成;或者所述中药组合物采用各成分混合后的活性物质提取物制备而成。
本申请的另一目的在于提供一种用于***炎的中药组合物的制备方法,采用所述中药组合物各成分原材料直接混合制备而成;或采用所述中药组合物各成分原材料混合后粉碎制备而成,粉碎采用了超微破壁粉碎。
作为本申请改进的技术方案,所述活性成分的提取包括如下步骤:
将中药组合物中各中药植物药材粉碎;
用提取剂过夜浸泡各中药植物粉料;
将浸泡后的中药植物粉料采用水煎煮或者低速渗漉提取;
将提取物浓缩,包括提取后的溶液通过旋转蒸发、喷雾干燥或真空干燥得到干膏粉末。
作为本申请改进的技术方案,用提取剂过夜浸泡各中药植物粉料过程中:提取剂为水或乙醇;提取温度为60-100℃;提取时间为1-3小时;提取次数为1-3次;提取剂为乙醇时,乙醇浓度为35%-95%。
本申请的另一目的是提供用于***的中药组合物在制备中药制剂中的应用。
有益效果
本申请的目的是为了解决现有治疗***炎存在口服药物副作用大,靶向不明确,药效不集中,治愈后容易复发,注射治疗技术要求比较高,患者痛苦大,从而提供一种新的中药组合物。尤其是针对慢性***炎患者存在的尿急、尿频、尿痛、膀胱发炎、下腹部胀痛等症状的改善,从而提高患者的生活质量。
本专利组方中各药材组分明确,药理作用明显,蚕蛹含有多种有益人体健康的药理活性成分,其中不饱和脂肪酸较高,不饱和脂肪酸可以改善***微环境,降低血液粘稠度,改善血液微循环,增强细胞活力,促进细胞新陈代谢,不饱和脂肪酸中以α-亚麻酸居多,α-亚麻酸具有很好的消炎、抗感染作用,同时提高机体免疫力;另外含有的多种维生素、微量元素、甲壳素、抗菌肽、溶菌酶等活性成分对于补充人体营养物质、提高人体免疫力有重要的作用。酸角中含有大量丰富的氨基酸,其中包括人体必需氨基酸苯丙氨酸、赖氨酸、苏氨酸、色氨酸等、编码蛋白质合成的丙氨酸、脯氨酸、谷氨酸、缬氨酸等,还有一些有药理活性作用的非必需氨基酸,氨基酸是构成人体营养所需蛋白质的基本物质,还可以起到营养强化作用,并提高人体免疫力。梓实具有利水消肿的作用,其含有的活性物质可以改善***血液循环,梓甙、脱-对-羟基苯甲酰梓甙可以通过钠利尿、氯利尿而利于排尿,改善因***疾病导致的排尿困难的症状。铁灯盏中含有人体必需氨基酸、Ca、Mg、Fe、Mn、Zn等微量元素,可以补充人体营养物质,另外咖啡酸、绿原酸、异绿原酸、二咖啡衍生物、菊糖等成分具有抗炎、提高机体免疫力的作用,对于***局部炎症因子具有很好的清除作用。
其组方的特点在于利用了每一组方药物的特性,并通过整体调理体质,达到缓解、治愈***疾病的目的。
(1)蚕蛹:蚕蛹有很高的营养价值和药用功能,自古以来一直作为滋补强身的食材,是“作为普通食品管理的食品新资源名单”中唯一的昆虫类食品干香蛹中含有50%左右的粗蛋白质,30%左右的油脂。蚕蛹能产生具有药理学活性的产物。这种活性产物能有效提高人体内的白细胞水平,从而提高人体内的免疫功能,并可有效延缓人体功能的衰老进程。蚕蛹中的不饱和脂肪酸的含量非常丰富,包括油酸、亚油酸和亚麻酸,不饱和脂肪酸占70.9%。不饱和脂肪酸对于维持人体正常的生理功能有极为重要的作用:保持细胞膜的相对流动性,以保证细胞的正常生理功能;使胆固醇酯化,降低血中胆固醇和甘油三酯,是促进婴幼儿生长发育和合成人体***素的必须物质;降低血液粘稠度,改善血液微循环;增强细胞活力,促进脂溶性维生素的消化和吸收。α-亚麻酸具有很好的消炎、抗感染作用,同时对降血压、降血脂以及提高免疫力有益。还含有维生素A、B、D等多种维生素,铁、锌、硒等微量元素以及少量粗纤维、甲壳素、抗菌肽、溶菌酶、多糖。蚕蛹中微量元素也非常丰富,是高钙高镁的食物。其钙含量是牛肉的76倍,鸡蛋的32倍,可强筋健骨;镁含量是牛肉的4倍,鸡蛋的12倍。此外,蚕蛹中还含有丰富的维生素及麦角甾醇等活性物质。
(2)酸角主要含有多种人体必需氨基酸、多糖、黄酮、生物碱、多不饱和脂肪酸以及多种微量元素等有效成分,具有消除腹部包块,止消渴,解毒、消炎、利尿、消肿的功效,含丰富的ω-3脂肪酸,可以降低心血管病的发生。
(3)梓实味甘,性平。主要含有果实含梓甙、脱-对-羟基苯甲酰梓甙、对-羟基苯甲酸、柠檬酸,种子含对-羟基苯甲酸、β-谷甾醇和脂肪酸等成分,具有利尿、抗炎、改善微循环等作用。
(4)铁灯盏主要含有各种人体必需氨基酸、咖啡酸、绿原酸、异绿原酸、二咖啡衍生物、菊糖、且含有Ca、Mg、Fe、Mn、Zn等人体必需的宏量元素和微量元素,具有利尿、降血压、增强免疫力、抗癌、抗突变、促生长、抗菌及抗真菌的作用。
(5)植物甾醇对人体具有较强的抗炎作用,具有能够抑制人体对胆固醇的吸收、促进胆固醇的降解代谢、抑制胆固醇的生化合成等作用,增强毛细血管循环,具有良好的抗氧性,对皮肤具有很高的渗透性,促进皮肤新陈代谢功效。
(6)γ-氨基丁酸是一种天然存在的非蛋白组成氨基酸,参与多种代谢活动,具有极其重要的生理功能,能促进人体内氨基酸代谢的平衡,调节免疫功能,延缓脑衰老机能,能补充人体抑制性神经递质,促进肾机能改善和保护作用。
(7)番茄红素是类胡萝卜素的一种,是目前在自然界的植物中被发现的最强抗氧化剂之一,可以有效的防治因衰老,免疫力下降引起的各种疾病,抗氧化能力是维生素E的100倍,相比其他抗氧化成分,番茄红素在体内会优先聚集到睾丸、肾上腺和***这三个组织中,帮助抗氧化和改善***增生症状。
(8)多聚果糖是一种优良的水溶性膳食纤维,同时还是一种很好的“益生元”,具有调节肠道菌群、增殖双歧杆菌、促进钙的吸收、促进免疫调节等保健功能,可减少肝脏毒素,能在肠中生成抗癌的有机酸,有显著的防癌功能。
(9)低聚半乳糖是一种新的功能性食品,通过高选择性地增殖双歧杆菌而使人体最大微生态***——肠道微生态***得以平衡,从而对宿主的营养、免疫和疾病的预防与治疗发挥着积极的作用,可以促进合成B族维生素、提高蛋白质的吸收利用率、促进矿物质吸收、抑制内毒素。
(10)蜂胶:内服补虚弱、化浊脂、止消渴;外用解毒消肿。具有抗炎、抗菌、抗病毒、抗氧化、增强免疫力、抗癌、促进细胞再生等作用。
(11)壳聚糖是一种机能性食品,能够营养细胞、活化失去活性的细胞、修复受损的细胞,通过提高机体的生理调节机能,强化人体免疫机能,大大增强人体抗疾病、抗疲劳、抗衰老的能力,发挥体内自然治愈力。
(12)桃胶属于植物性多糖营养物质,主要组成为半乳糖、鼠李糖、α-葡萄糖醛酸等,桃胶中的多糖类物质有助于增强肠道功能,有助于机体新陈代谢,黏多糖成分可以提高身体免疫力。
(13)库拉索芦荟凝胶是一种新资源食品,提高人体免疫力,清除自由基,缓解发炎等作用。
本申请的组成药物中含有的多糖类、黄酮类、甾醇类等活性成分以及维生素B、维生素C及各种氨基酸、微量元素、矿物质等营养成分可以提高机体免疫力、增加抑菌能力、平衡雄性激素水平、激活组织细胞、改善微循环、促进机体新陈代谢、补充营养。主要针对***炎症患者的尿急、尿频、尿痛、膀胱发炎、下腹部胀痛等症状具有很好的缓解作用。
具体实施方式
为使本申请实施例的目的和技术方案更加清楚,下面将结合本申请实施例,对本申请的技术方案进行清楚、完整地描述。显然,所描述的实施例是本申请的一部分实施例,而不是全部的实施例。基于所描述的本申请的实施例,本领域普通技术人员在无需创造性劳动的前提下所获得的所有其他实施例,都属于本申请保护的范围。
本技术领域技术人员可以理解,除非另外定义,这里使用的所有术语(包括技术术语和科学术语)具有与本申请所属领域中的普通技术人员的一般理解相同的意义。还应该理解的是,诸如通用字典中定义的那些术语应该被理解为具有与现有技术的上下文中的意义一致的意义,并且除非像这里一样定义,不会用理想化或过于正式的含义来解释。
本文中所述的份均为重量份。
本申请的目的是为了解决现有治疗***炎存在口服药物副作用大,靶向不明确,药效不集中,治愈后容易复发,注射治疗技术要求比较高,患者痛苦大,从而提供一种新的中药组合物。尤其是针对慢性***炎患者存在的尿急、尿频、尿痛、膀胱发炎、下腹部胀痛等症状的改善,从而提高患者的生活质量。
一种用于***炎的中药组合物,包括如下重量份的各物质:
其中,上述成分可采用各物质的原材料,也可以采用各物质的活性成分提取物,蚕蛹的提取物主要为不饱和脂肪酸;
酸角的活性提取物主要为:ω-3脂肪酸、多种氨基酸;
梓实的活性提取物主要为:果实含梓甙、脱-对-羟基苯甲酰梓甙、对-羟基苯甲酸、柠檬酸,种子含对-羟基苯甲酸、β-谷甾醇和脂肪酸等成分;
铁灯盏各种人体必需氨基酸、咖啡酸、绿原酸、异绿原酸、二咖啡衍生物、菊糖、且含有Ca、Mg、Fe、Mn、Zn等人体必需的宏量元素和微量元素。
为了丰富各组合物的营养成分,也为了丰富组合物的制剂形式,还包括辅料,辅料包括植物甾醇、γ-氨基丁酸、番茄红素、多聚果糖、低聚半乳糖、蜂胶、壳聚糖、桃胶或库拉索芦荟凝胶中的一种或多种。所述辅料的总重量份为0.9-5.6份。
如中药组合物包括:
为了方便引用,所述中药组合物采用代用茶、颗粒剂、胶囊剂、片剂或散剂形式呈现。
本申请的另一目的在于提供一种用于***炎的中药组合物的制备方法,所述中药组合物采用各成分的活性物质提取物制备而成;或者所述中药组合物采用各成分混合后的活性物质提取物制备而成。
本申请的另一目的在于提供一种用于***炎的中药组合物的制备方法,采用所述中药组合物各成分原材料直接混合制备而成;或采用所述中药组合物各成分原材料混合后粉碎制备而成,粉碎采用了超微破壁粉碎。
作为本申请改进的技术方案,所述活性成分的提取包括如下步骤:
将中药组合物中各中药植物药材粉碎;
用提取剂过夜浸泡各中药植物粉料;用提取剂过夜浸泡各中药植物粉料过程中:提取剂为水或乙醇;提取温度为60-100℃,优选地为70-90℃;提取时间为1-3小时;提取次数为1-3次;提取剂为乙醇时,乙醇浓度为35%-95%;
将浸泡后的中药植物粉料采用水煎煮或者低速渗漉提取;
将提取物浓缩,包括提取后的溶液通过旋转蒸发、喷雾干燥或真空干燥得到干膏粉末。
实施案例1
按照下述组分及用量称取各原料药:
将充分干燥后的蚕蛹30份、酸角10份、梓实40份、铁灯盏50份粉碎混合,加入可食用性硅胶5份,装袋后干燥环境中保存。本实施例中可食用硅胶主要用于辅助保存,并非本申请中药组合物的成分。
对比例1
将充分干燥后的酸角10份、梓实40份、铁灯盏50份粉碎混合,加入可食用性硅胶5份,装袋后干燥环境中保存。
对比例2
将充分干燥后的蚕蛹30份、梓实40份、铁灯盏50份粉碎混合,加入可食用性硅胶5份,装袋后干燥环境中保存。
对比例3
将充分干燥后的蚕蛹30份、酸角10份、铁灯盏50份粉碎混合,加入可食用性硅胶5份,装袋后干燥环境中保存。
对比例4
将充分干燥后的蚕蛹30份、酸角10份、梓实40份粉碎混合,加入可食用性硅胶5份,装袋后干燥环境中保存。
本专利进行了组方中不同组分分别组合对比例的动物实验验证。
1.材料与方法
1.1动物Wistar清洁级大鼠,雄性,250~300g,购于湘雅医学院动物实验中心。
1.2药物
药物1组(实施例1):将充分干燥后的蚕蛹30份、酸角10份、梓实40份、铁灯盏50份粉碎混合,加入可食用性硅胶5份,装袋后干燥环境中保存。
药物2组(对比例1):将充分干燥后的酸角10份、梓实40份、铁灯盏50份粉碎混合,加入可食用性硅胶5份,装袋后干燥环境中保存。
药物3组(对比例2):将充分干燥后的蚕蛹30份、梓实40份、铁灯盏50份粉碎混合,加入可食用性硅胶5份,装袋后干燥环境中保存。
药物4组(对比例3):将充分干燥后的蚕蛹30份、酸角10份、铁灯盏50份粉碎混合,加入可食用性硅胶5份,装袋后干燥环境中保存。
药物5组(对比例4):将充分干燥后的蚕蛹30份、酸角10份、梓实40份粉碎混合,加入可食用性硅胶5份,装袋后干燥环境中保存。
模型药物:消痔灵注射液:吉林集安益盛药业股份有限公司。(批号:091004)
1.3动物模型建立
取成年雄性大鼠(250~300g左右)用戊巴比妥钠(30mg/Kg)麻醉,在无菌操作条件下,于下腹正中切口约1cm直达腹腔,小心提出两侧精囊及附于精囊内侧的***贝叶,随机取7只大鼠直接缝合腹壁作为空白对照组,其他大鼠于两侧***背叶内分别注入消痔灵注射液0.15ml,缝合腹壁。
1.4分组与给药
术后第7天将大鼠随机分成6组(除去空白对照组),即模型组、药物组1组(喂食本发明的药物1组药物0.4g/kg)、药物2组(喂食本发明的药物2组药物0.4g/kg)、药物3组(喂食本发明的药物3组药物0.4g/kg),药物4组(喂食本发明的药物4组药物0.4g/kg)、药物5组(喂食本发明的药物5组药物0.4g/kg),每组7只,按体重连续灌胃给药30天,每天给药1次,正常组和模型组给予等量生理盐水。
1.5大鼠解剖和病理观察
末次给药后处死大鼠,颈动脉取血,离心,取血清留用。解剖,肉眼观察***病变状态,剖取***组织,肉眼观察***病变状态并称湿重,计算***指数;取***按摩液10μL放入白细胞稀释液中,光学显微镜下观察,计数白细胞总数;另取一滴***液涂片,镜下观察卵磷脂小体密度,评分标准为:满视野4分,1/2视野3分,1/4视野2分,低倍镜下仅见数个为1分。取另一侧***侧叶,置于10%***溶液中固定,常规脱水透明,石蜡切片一部分HE染色,于光学显微镜下观察组织形态变化。
2实验结果
2.1肉眼观察
肉眼观察解剖后的大鼠***组织,空白对照组的***组织呈粉红色,质软、有光泽、与周围组织无粘连,无结节无硬化。模型组***组织呈棕黄色和黑色,普遍与周围组织粘连,呈充血或瘀血状态,部分可见结节和硬化,并有水肿。药物1组的***腺体呈粉红色,质软、有光泽、与周围组织无粘连,无结节无硬化,与正常组近似,药物2组、药物3组、药物4组、药物5组的***腺体均呈不同程度风热黄色或偏黑色,且与周围组织有轻度黏连,部分呈充血或淤血状态,有轻微水肿情况。该结果说明该专利的组成是最佳组成,成分缺一不可。
2.2大鼠***液中白细胞数和卵磷脂小体密度的变化
表1药物对***液白细胞数、卵磷脂小体密度、***指数的影响
从表1中可以看到,模型组的卵磷脂小体密度明显比正常组小,药物1组的卵磷脂小体密度比模型组要大,跟正常组的数值差别不大,其他药物组的卵磷脂小体密度跟模型组相差不大。药物1组可减少***炎大鼠的白细胞总数,增加卵磷脂小体密度,降低***指数,其治愈效果明显,其他药物组均未达到药物1组的治疗效果,说明药物1组的组合是最佳组合,缺少任一组分均达不到治疗效果。
2.3病理学观察结果
用BX~50型Olympus光学显微镜观察正常组、模型组和药物组的组织形态变化:(1)空白对照组:未见肉芽肿性病变,间质有少量炎症细胞浸润。(2)模型组:***组织内见肉芽肿性病变,腺腔内可见异物结晶,间质见大量炎性细胞浸润。(3)药物1组:肉芽肿性病变部分明显减少甚至消失,间质浸润的炎症细胞数量明显减少。(4)药物2组、药物3组、药物4组、药物5组:***组织内有轻微肉芽肿性病变,间质有少量炎性细胞浸润。
实施案例2
按照下述组分及用量称取各原料药:
将充分干燥后的蚕蛹50份、酸角20份、梓实20份、铁灯盏30份粉碎混合,加入药物总重量10倍的水浸泡放置过夜,水煎煮两次,每次1小时,过滤,滤液100℃减压下蒸除水分,得到密度为1.20-1.30的浓缩膏,喷雾干燥得干粉,配伍相应的辅料:番茄红素0.2份、低聚半乳糖0.2份、蜂胶0.5份混合,加入可食用性硅胶5份,装袋干燥处存放。
实施案例3
将充分干燥后的梓实40份、铁灯盏30份粉碎,加入药物总重量10倍的水浸泡放置过夜,水煎煮两次,每次3小时,过滤,滤液60℃减压下蒸除水分,得到密度为1.20-1.30的浓缩膏,喷雾干燥得干粉,后加入30份蚕蛹、20份酸角后配伍相应的辅料:番茄红素0.2份、低聚半乳糖0.2份、蜂胶0.5份混合,加入可食用性硅胶5份,装袋干燥处存放。
实施案例4
按照下述组分及用量称取各原料药:
将充分干燥后的蚕蛹20份、酸角50份、梓实60份、铁灯盏10份粉碎混合,加入药物总重量10倍的水浸泡放置过夜,水煎煮三次,每次1小时,过滤,滤液70℃减压下蒸除水分,得到密度为1.20-1.30的浓缩膏,喷雾干燥得干粉,配伍相应的辅料:番茄红素0.2份、低聚半乳糖0.2份、植物甾醇2份、蜂胶0.5份、壳聚糖0.5份、库拉索芦荟凝胶2份混合,加入粘合剂制成颗粒,装袋干燥处存放。
实施案例5
按照下述组分及用量称取各原料药:
将充分干燥后的蚕蛹40份、酸角20份、梓实40份、铁灯盏30份粉碎混合,加入药物总重量10倍的水浸泡放置过夜,水煎煮两次,每次3小时,过滤,滤液70℃减压下蒸除水分,得到密度为1.2-1.3的浓缩膏,喷雾干燥得干粉,配伍相应的辅料:γ-氨基丁酸0.01份、蜂胶0.5份、壳聚糖0.5份混合,加入粘合剂制成颗粒,装袋干燥处存放。
实施案例6
按照下述组分及用量称取各原料药:
将充分干燥后的蚕蛹30份、酸角20份、梓实50份、铁灯盏40份加入药物总重量10倍的浸泡放置过夜,水煎煮两次,每次2小时,过滤,滤液70℃减压下蒸除水分,得到密度为1.2-1.3的浓缩膏,喷雾干燥得干粉,配伍相应的辅料:多聚果糖0.5份、γ-氨基丁酸0.01份、蜂胶0.5份、壳聚糖0.5份、桃胶2份、库拉索芦荟凝胶2份混合,加入硬脂酸镁直接压片或加入粘合剂制成颗粒后加硬脂酸镁压片,瓶装或铝塑板包装。
典型案例
典型病例一:纪先生,男,43岁。5年前被诊断为非细菌性***炎。长期尿急、尿频、尿路疼痛,造成长期睡眠不好。去年7月开始服用本申请实施案例1代用茶制剂,采用每天服用3次,一次一包(10g),15天一个疗程。一个疗程后尿路通畅,之前的不适症状得到很大程度的缓解。继续服用3个疗程,按照NIH-CPSI症状评分标准进行对比自测,其***炎症得到治愈,炎症临床症状基本消失。
典型病例二:庄先生,男,50岁,长期慢性***炎,***及下腹部胀痛,前期服用本申请实施案例2散剂,采用每天服用3次,一次一包(5g),15天一个疗程,服用两个疗程后,尿频、尿急、尿路疼痛症状缓解,继续服用4个疗程,以上症状均消失。
典型案例三:冯先生,男,39岁,政府部门职员,因工作性质,近期发现小便排出不利,小腹坠胀疼痛。后到医院检查诊断为慢性***炎,并引发膀胱炎症。服用西药药物治疗效果不明显。一个月前服用本申请实施案例3的散剂,采用每天服用3次,一次一包(5g),15天一个疗程,一周后,小便排出较前顺畅,随后继续服用两个疗程,小便完全顺畅,小腹胀痛感消失,膀胱炎症亦减轻,继续服用一个疗程,无腹部疼痛。
典型案例四:李先生,男,40岁。自诉患有慢性***炎5年,用过各种方法治疗均无效,主要症状是下腹部胀痛、坐立难安、尿频、尿急、尿痛,严重影响到生活。经过服用本申请实施案例4颗粒剂,采用每天服用3次,一次一包(10g),15天一个疗程,服用,1个疗程,症状减轻,继续服用4个疗程,不适症状消失,***炎症消失,生活质量得到很大改善。
典型案例五:周先生,男,45岁,01年被诊断为非细菌性***炎。历经15年各种治疗均不见效,长期尿急、尿频、尿路疼痛,严重影响到生活质量。2019年1月12日开始服用本申请实施例5颗粒,采用每天服用3次,一次一包(10g),15天一个疗程。一周后尿路通畅,之前的不适症状得到很大程度的缓解。继续服用6周,炎症临床症状基本消失。
典型案例六:肖先生,男,46岁,两年前曾有小腹***不适感,同时尿频,由于症状不严重,不经常发作,未进行正规治疗,近段时间症状加重,夜尿频繁,严重影响工作和生活,服用西药效果前期还好,总反复,服用本申请实施案例6片剂,采用每天服用3次,每次3片(0.7g/片),15天一个疗程,服用一个疗程,症状减轻,继续服用4个疗程,患者痊愈,随访3个月没有复发。
另需要强调的是:以上所述仅为本申请的优选案例而已,并不用于限制本申请,对于本领域的技术人员来说,可以根据本申请所提供的方案,增加或者减少其中的成分或步骤,或者将本申请用于其他的与本申请接近的基数领域,均属本申请的保护范围。
Claims (9)
2.根据权利要求1所述的一种用于***炎的中药组合物,其特征在于,还包括辅料,辅料包括植物甾醇、γ-氨基丁酸、番茄红素、多聚果糖、低聚半乳糖、蜂胶、壳聚糖、桃胶或库拉索芦荟凝胶中的一种或多种。
3.根据权利要求2所述的一种用于***炎的中药组合物,其特征在于,所述辅料的总重量份为0.9-5.6份。
4.根据权利要求1所述的一种用于***炎的中药组合物,其特征在于,所述中药组合物采用代用茶、颗粒剂、胶囊剂、片剂或散剂形式呈现。
5.一种基于权利要求1-4任一所述的用于***炎的中药组合物的制备方法,其特征在于,所述中药组合物采用各成分的活性物质提取物制备而成;或者所述中药组合物采用各成分混合后的活性物质提取物制备而成。
6.根据权利要求5所述的用于***炎的中药组合物的制备方法,其特征在于,所述活性成分的提取包括如下步骤:
将中药组合物中各中药植物药材粉碎;
用提取剂过夜浸泡各中药植物粉料;
将浸泡后的中药植物粉料采用水煎煮或者低速渗漉提取;
将提取物浓缩,包括提取后的溶液通过旋转蒸发、喷雾干燥或真空干燥得到干膏粉末。
7.根据权利要求6所述的用于***炎的中药组合物的制备方法,其特征在于,用提取剂过夜浸泡各中药植物粉料过程中:提取剂为水或乙醇;提取温度为60-100℃;提取时间为1-3小时;提取次数为1-3次;提取剂为乙醇时,乙醇浓度为35%-95%。
8.一种基于权利要求1-4任一所述的用于***炎的中药组合物的制备方法,其特征在于,采用所述中药组合物各成分原材料直接混合制备而成;或采用所述中药组合物各成分原材料混合后粉碎制备而成。
9.权利要求1-3任一项所述的用于***的中药组合物在制备中药制剂中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911358094.9A CN110859912A (zh) | 2019-12-25 | 2019-12-25 | 一种用于***炎的中药组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911358094.9A CN110859912A (zh) | 2019-12-25 | 2019-12-25 | 一种用于***炎的中药组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110859912A true CN110859912A (zh) | 2020-03-06 |
Family
ID=69660003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911358094.9A Pending CN110859912A (zh) | 2019-12-25 | 2019-12-25 | 一种用于***炎的中药组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110859912A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110917249A (zh) * | 2019-12-25 | 2020-03-27 | 湖南湘源美东医药科技有限公司 | 一种用于***的中药组合物及其制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102077944A (zh) * | 2010-09-20 | 2011-06-01 | 王强 | 一种***患者专用的海洋特膳食品 |
CN104491661A (zh) * | 2015-01-23 | 2015-04-08 | 长沙美东医药科技有限公司 | 一种用于治疗***炎或***增生的中药组合物 |
CN104839666A (zh) * | 2015-04-11 | 2015-08-19 | 劲膳美生物科技股份有限公司 | ***炎医学配方食品 |
CN107714814A (zh) * | 2017-10-02 | 2018-02-23 | 刘新江 | 蚕蛹虫草制剂 |
CN110226744A (zh) * | 2019-07-05 | 2019-09-13 | 上海奥医生物医药科技有限公司 | 一种***炎专用型临床营养配方及其制备方法 |
-
2019
- 2019-12-25 CN CN201911358094.9A patent/CN110859912A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102077944A (zh) * | 2010-09-20 | 2011-06-01 | 王强 | 一种***患者专用的海洋特膳食品 |
CN104491661A (zh) * | 2015-01-23 | 2015-04-08 | 长沙美东医药科技有限公司 | 一种用于治疗***炎或***增生的中药组合物 |
CN104839666A (zh) * | 2015-04-11 | 2015-08-19 | 劲膳美生物科技股份有限公司 | ***炎医学配方食品 |
CN107714814A (zh) * | 2017-10-02 | 2018-02-23 | 刘新江 | 蚕蛹虫草制剂 |
CN110226744A (zh) * | 2019-07-05 | 2019-09-13 | 上海奥医生物医药科技有限公司 | 一种***炎专用型临床营养配方及其制备方法 |
Non-Patent Citations (1)
Title |
---|
臧郁文: "《中国针灸临床治疗学》", 31 October 2003, 青岛出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110917249A (zh) * | 2019-12-25 | 2020-03-27 | 湖南湘源美东医药科技有限公司 | 一种用于***的中药组合物及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109123643A (zh) | 一种谷物代餐球的制备方法 | |
CN105942498A (zh) | 具有治疗糖尿病作用的功能性营养食品组合及其制备方法 | |
CN110354204B (zh) | 一种具有明目功效的组合物及其制备、应用方法 | |
CN112772813A (zh) | 一种提高免疫力缓解疲劳的复合肽固体饮料及其制备方法 | |
CN105412623A (zh) | 治疗脂肪肝、***炎、肾痛肾炎、高血压及糖尿病的药物 | |
CN105232907A (zh) | 一种补肾壮阳饮料及其制备方法 | |
CN110859871A (zh) | 一种用于***炎的组合物及其制备方法 | |
KR102218823B1 (ko) | 지치 추출물을 포함하는 항알러지용 조성물 | |
CN108324921B (zh) | 一种具有祛除囊肿、保护胃粘膜功能的药物组合物及其制备方法 | |
CN113197315B (zh) | 一种具有增强男性性功能的食品组合物及其制备方法 | |
CN101554362A (zh) | 一种天然产物的组方及制剂 | |
CN104857154A (zh) | 一种治疗“三高”症的中药组合物及其制备方法 | |
CN113633702A (zh) | 一种舒缓老年皮肤瘙痒症的傣药组合物及其制剂与应用 | |
CN103877486B (zh) | 用于促升放化疗后白细胞数量的药物及其制备方法 | |
CN112791175A (zh) | 提高人体新陈代谢机能和排出代谢废物的中西药组合物及其制备方法 | |
CN105249440A (zh) | 一种阿胶糕 | |
CN108114266A (zh) | 一种治疗慢性***炎的中药组合物及其制备方法 | |
CN110859912A (zh) | 一种用于***炎的中药组合物及其制备方法和应用 | |
CN106798854B (zh) | 余甘桑叶片及其制备方法 | |
CN105394758A (zh) | 一种改善酸性体质阻断人体毒素的青梅酵素粉及制备方法 | |
CN109549958A (zh) | 治疗激素依赖性皮炎的组合物及其制备方法 | |
CN104739964A (zh) | 一种蜗牛解酒制剂及其制作方法 | |
CN113633689A (zh) | 低聚半乳糖醛酸聚糖中药复合制剂、制备方法及应用 | |
CN102640893B (zh) | 一种黑麦芽全草复合营养剂及其制备方法 | |
CN108210557B (zh) | 一种用于消除胀气、胃黏膜修复及护理的食用生物制品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200306 |